From: Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer
 | Ezrin | EzrinThr-567 | EzrinTyr-353 | ||||
---|---|---|---|---|---|---|---|
Diagnosis | No. of cases | Positive rate | Strongly positive rate | Positive rate | Strongly positive rate | Positive rate | Strongly positive rate |
 |  | (+ ~ +++, %) | (++ ~ +++, %) | (+ ~ +++, %) | (++ ~ +++, %) | (+ ~ +++, %) | (++ ~ +++, %) |
NSCLC | 150 | 94 (62.7%)** | 61 (40.7%)** | 95 (63.3%)** | 68 (45.3%)** | 107 (71.3%)** | 72 (48.0%)** |
Adjacent non-tumor | 150 | 47 (31.3%) | 5 (3.3%) | 21 (14.0%) | 7 (4.7%) | 17 (11.3%) | 2 (1.3%) |
Normal lung tissues | 14 | 5 (35.7%) | 0 (0.0%) | 2 (14.3%) | 0 (0.0%) | 1 (7.1%) | 0 (0.0%) |